BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32439360)

  • 1. Preclinical study of influenza bivalent vaccine delivered with a two compartmental microneedle array.
    Jeong HR; Bae JY; Park JH; Baek SK; Kim G; Park MS; Park JH
    J Control Release; 2020 Aug; 324():280-288. PubMed ID: 32439360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants.
    Shin Y; Kim J; Seok JH; Park H; Cha HR; Ko SH; Lee JM; Park MS; Park JH
    Sci Rep; 2022 Jul; 12(1):12189. PubMed ID: 35842468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation Approach that Enables the Coating of a Stable Influenza Vaccine on a Transdermal Microneedle Patch.
    Ameri M; Ao Y; Lewis H
    AAPS PharmSciTech; 2021 Jun; 22(5):175. PubMed ID: 34114100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microneedle-based vaccines.
    Prausnitz MR; Mikszta JA; Cormier M; Andrianov AK
    Curr Top Microbiol Immunol; 2009; 333():369-93. PubMed ID: 19768415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
    Kommareddy S; Baudner BC; Oh S; Kwon SY; Singh M; O'Hagan DT
    J Pharm Sci; 2012 Mar; 101(3):1021-7. PubMed ID: 22190403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
    Fernando GJP; Hickling J; Jayashi Flores CM; Griffin P; Anderson CD; Skinner SR; Davies C; Witham K; Pryor M; Bodle J; Rockman S; Frazer IH; Forster AH
    Vaccine; 2018 Jun; 36(26):3779-3788. PubMed ID: 29779922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable microneedles with an immune-boosting function for effective intradermal influenza vaccination.
    Chen YH; Lai KY; Chiu YH; Wu YW; Shiau AL; Chen MC
    Acta Biomater; 2019 Oct; 97():230-238. PubMed ID: 31362139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of H1N1 microneedles by a low-temperature process without a stabilizer.
    Jeong HR; Park S; Park JH; Bae JY; Kim GY; Baek SK; Park MS; Park JH
    Eur J Pharm Biopharm; 2019 Oct; 143():1-7. PubMed ID: 31398438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses.
    Fernando GJ; Zhang J; Ng HI; Haigh OL; Yukiko SR; Kendall MA
    J Control Release; 2016 Sep; 237():35-41. PubMed ID: 27381247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.
    Zhu W; Pewin W; Wang C; Luo Y; Gonzalez GX; Mohan T; Prausnitz MR; Wang BZ
    J Control Release; 2017 Sep; 261():1-9. PubMed ID: 28642154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods.
    Vrdoljak A; Allen EA; Ferrara F; Temperton NJ; Crean AM; Moore AC
    J Control Release; 2016 Mar; 225():192-204. PubMed ID: 26774221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.
    Vassilieva EV; Kalluri H; McAllister D; Taherbhai MT; Esser ES; Pewin WP; Pulit-Penaloza JA; Prausnitz MR; Compans RW; Skountzou I
    Drug Deliv Transl Res; 2015 Aug; 5(4):360-71. PubMed ID: 25895053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains.
    Jang YH; Lee EY; Byun YH; Jung EJ; Lee YJ; Lee YH; Lee KH; Lee J; Seong BL
    Vaccine; 2014 Jan; 32(5):535-43. PubMed ID: 24342248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microneedle delivery of trivalent influenza vaccine to the skin induces long-term cross-protection.
    Kim YC; Lee SH; Choi WH; Choi HJ; Goo TW; Lee JH; Quan FS
    J Drug Target; 2016 Dec; 24(10):943-951. PubMed ID: 26957023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.